• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore March 28 Strides Arcolab has said it has received tentative USFDA approval for yet another anti-AIDS drug — Efavirenz tablets. The approval comes under the expedited review provisions of the US President's Emergency Plan for AIDS Relief programme.

Efavirenz is a generic version of Bristol-Myers Squibb's Sustiva, which prevents the AIDS virus from reproducing in cells. Efavirenz is used in combination with other anti-retroviral agents (ARVs) to treat HIV infections and is a key component of drug regimens for patients who are simultaneously being treated for tuberculosis.

Strides says it has ANDA/NDA (abbreviated new drug application) approvals for all first-line ARVs.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Glenmark in patent challenge over cholesterol drug

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line